Navigation Links
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review

NEW ORLEANS and CARLSBAD, Calif., Nov. 6

/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Isis' cardiovascular program review of development and

late-stage research candidates, including presentations


-- Dr. Erik Stroes reporting top line data from an ongoing

Phase 2 mipomersen liver imaging study

-- Dr. Evan Stein providing an update on an open-label

extension study of mipomersen in subjects with familial


When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.

PT/7:00 p.m. ET)


How: Live on the Internet. Simply log onto the website listed


Contacts: Kristina Lemonidis

Associate Director, Corporate Development

Isis Pharmaceuticals, Inc.

(760) 603-2490

Amy Blackley, Ph.D.

Manager, Corporate Communications

Isis Pharmaceuticals, Inc.

(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. GNC Schedules Conference Call and Webcast to Report 3rd Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. STERIS Corporation Announces Webcast of Analyst Conference
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11
6. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
7. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
9. Sunrise to Host Conference Call and Webcast to Discuss the Companys Financial Results for the Third Quarter 2008
10. Webcast Alert: Air Methods Corporation Announces Third Quarter 2008 Financial Results
11. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: